Evidence map›Paper›PMID 40121357›Full record

ArticleCancer gene therapy2025

Therapeutic potential of synthetic microRNA mimics based on the miR-15/107 consensus sequence.

Glen Reid, Marissa Williams, Yuen Yee Cheng, Kadir Sarun, Patrick Winata, Michaela B Kirschner, Nancy Mugridge, Jocelyn Weiss, Mark Molloy, Himanshu Brahmbhatt and 2 more

Abstract read
In one paragraph

Article in Cancer gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Glen ReidAsbestos and Dust Diseases Research Institute (ADDRI), Sydney, NSW, Australia. glen.reid@otago.ac.nz.ORCID http://orcid.org/0000-0001-6465-5223
Marissa WilliamsAsbestos and Dust Diseases Research Institute (ADDRI), Sydney, NSW, Australia.
Yuen Yee ChengAsbestos and Dust Diseases Research Institute (ADDRI), Sydney, NSW, Australia.
Kadir SarunAsbestos and Dust Diseases Research Institute (ADDRI), Sydney, NSW, Australia.ORCID http://orcid.org/0009-0002-0297-6691
Patrick WinataAsbestos and Dust Diseases Research Institute (ADDRI), Sydney, NSW, Australia.
Michaela B KirschnerAsbestos and Dust Diseases Research Institute (ADDRI), Sydney, NSW, Australia.ORCID http://orcid.org/0000-0001-7444-9829
Nancy MugridgeEnGeneIC Ltd, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0001-9933-0509
Jocelyn WeissEnGeneIC Ltd, Sydney, NSW, Australia.ORCID http://orcid.org/0009-0000-2871-8258
Mark MolloyThe Australian Proteome Analysis Facility, Macquarie University, Sydney, NSW, Australia.
Himanshu BrahmbhattEnGeneIC Ltd, Sydney, NSW, Australia.
Jennifer MacDiarmidEnGeneIC Ltd, Sydney, NSW, Australia.
Nico van ZandwijkSchool of Medicine, University of Sydney, Sydney, NSW, Australia.

Funding

Cancer Institute NSW (Cancer Institute New South Wales) 11/TPG/3-06
6 · The paper itself

Abstract

MicroRNA expression is frequently suppressed in cancer, and previously we demonstrated coordinate downregulation of multiple related microRNAs of the miR-15/107 group in malignant pleural mesothelioma (PM). From an alignment of the miR-15 family and the related miR-103/107, we derived a consensus sequence and used this to generate synthetic mimics. The synthetic mimics displayed tumour suppressor activity in PM cells in vitro, which was greater than that of a mimic based on the native miR-16 sequence. These mimics were also growth inhibitory in cells from non-small cell lung (NSCLC), prostate, breast and colorectal cancer, and sensitised all cell lines to the chemotherapeutic drug gemcitabine. The increased activity corresponded to enhanced inhibition of the expression of target genes and was associated with an increase in predicted binding to target sites, and proteomic analysis revealed a strong effect on proteins involved in RNA and DNA processes. Applying the novel consensus mimics to xenograft models of PM and NSCLC in vivo using EGFR-targeted nanocells loaded with mimic led to tumour growth inhibition. These results suggest that mimics based on the consensus sequence of the miR-15/107 group have therapeutic potential in a range of cancer types.

Indexed as

MesotheliomaMicroRNAsAnimalsCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationConsensus SequenceGene Expression Regulation, NeoplasticHumansLung NeoplasmsMesothelioma, MalignantMiceXenograft Model Antitumor AssaysMicroRNAsMIRN15 microRNA, human

Identifiers

PMID40121357
PMCPMC11976272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.